Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus

Imagem de Miniatura
Arquivos
art_BARBOSA_Immune_response_and_tolerability_of_varicella_vaccine_in_2012.PDF (444.3 KB)
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2012
Editora
CLINICAL & EXPER RHEUMATOLOGY
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
BARBOSA, C. M. P. L.
TERRERI, M. T. R. A.
ROSARIO, P. O.
MORAES-PINTO, M. I. de
HILARIO, M. O. E.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, v.30, n.5, p.791-798, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives The aim of the present paper is to evaluate the immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Methods We performed a prospective and controlled study on a group of 54 SLE patients that were chosen at random to be or not to be vaccinated (28 were vaccinated and 26 were not). Twenty-eight healthy controls, of matching age and sex were also vaccinated. All were submitted to a questionnaire, physical evaluation and laboratory assays: lymphocyte immuno-phenotyping by flow cytometry, plasma varicella zoster virus (VZV) serology by ELISA and in vitro interferon gamma (IFN gamma) production by T-cells after stimulus with VZV antigen. They were evaluated before vaccination and at 30, 45, 180 and 360 days afterwards. Results We did not observe any differences in the frequency of adverse events in both vaccinated groups. At study entry, all individuals were seropositive for VZV antibodies. The serum VZV antibody titres similarly increased after vaccination. The frequency of flares and the SLEDAI score were also similar among the patients. Thirty days after vaccination the production of IFN gamma specific to VZV was lower in the SLE group compared to healthy, controls. In the follow-up we observed 4 cases of herpes zoster in the SLE unvaccinated group, but no zoster in the vaccinated group. Conclusion The varicella vaccine was well tolerated in SLE group, who had pre-existing immunity to varicella. The varicella vaccine immunogenicity measurement by serum antibody titres was appropriate. The incidence of HZ was lower in the vaccinated lupus group.
Palavras-chave
herpes zoster, immunocompromised host, systemic lupus erythematosus, vaccine, varicella
URI
https://observatorio.fm.usp.br/handle/OPI/16441
Referências
  1. Asanuma H, 2000, J INFECT DIS, V181, P859, DOI 10.1086/315347
  2. BERMAS BL, 1994, J CLIN IMMUNOL, V14, P169, DOI 10.1007/BF01533366
  3. Berner BR, 2005, CELL IMMUNOL, V235, P29, DOI 10.1016/j.cellimm.2005.06.010
  4. BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
  5. Clemens SA, 1999, J PEDIAT RIO J, V75, P433
  6. Conti F, 2008, AUTOIMMUN REV, V8, P124, DOI 10.1016/j.autrev.2008.07.007
  7. de Ory F, 2006, J CLIN VIROL, V36, P111, DOI 10.1016/j.jcv.2006.01.017
  8. Derryck A, 1998, PEDIATR INFECT DIS J, V17, P931, DOI 10.1097/00006454-199810000-00023
  9. GERSHON A, 1997, J INFECT DIS, V176, P1946
  10. Gershon AA, 2009, PEDIATR INFECT DIS J, V28, P653, DOI 10.1097/INF.0b013e3181998f06
  11. Green MRJ, 2007, ARTHRITIS RHEUM-US, V56, P303, DOI 10.1002/art.22326
  12. Green MRJ, 2005, CLIN EXP IMMUNOL, V141, P165, DOI 10.1111/j.1365-2249.2005.02822.x
  13. Harpaz Rafael, 2008, MMWR Recomm Rep, V57, P1
  14. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  15. HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9
  16. Kang TY, 2005, RHEUMATOL INT, V25, P97, DOI 10.1007/s00296-003-0403-3
  17. Lee PPW, 2006, PEDIATR INFECT DIS J, V25, P728, DOI 10.1097/01.inf.0000226841.03751.1f
  18. LEVIN M, 1996, VARICELLA VACCINE, P657
  19. Levin MJ, 2008, J INFECT DIS, V197, P825, DOI 10.1086/528696
  20. Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048
  21. LEVIN MJ, 1992, J INFECT DIS, V166, P253
  22. MILLER AE, 1980, NEUROLOGY, V30, P582
  23. Millet A, 2009, EUR J INTERN MED, V20, P236, DOI 10.1016/j.ejim.2008.07.017
  24. MYIAMOTO M, 2011, LUPUS, V20, P736
  25. NAGASAWA K, 1990, ANN RHEUM DIS, V49, P630, DOI 10.1136/ard.49.8.630
  26. O'Neill SG, 2006, LUPUS, V15, P778, DOI 10.1177/0961203306069355
  27. Ono Erika, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P165, DOI 10.1590/S0036-46652004000300008
  28. Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
  29. Park HB, 2004, J RHEUMATOL, V31, P2151
  30. Petursson G, 1998, PEDIATR INFECT DIS J, V17, P905, DOI 10.1097/00006454-199810000-00011
  31. PICK-ERING LK, 2009, RED BOOK 2009 REPORT, P380
  32. Pickering LK, 2009, RED BOOK 2009 REPORT, P68
  33. Rahier JF, 2010, RHEUMATOLOGY, V49, P1815, DOI 10.1093/rheumatology/keq183
  34. SILVA CAA, 2009, BRAS J RHEUMATOL, V49, P562
  35. Takahashi M, 2001, PEDIATR DRUGS, V3, P285, DOI 10.2165/00128072-200103040-00005
  36. TSOKOS GC, 1986, ARTHRITIS RHEUM, V29, P1210, DOI 10.1002/art.1780291005
  37. van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216
  38. Weinberg A, 2004, J INFECT DIS, V190, P267, DOI 10.1086/422011
  39. Weiss JE, 2007, J RHEUMATOL, V34, P1341
  40. Wood SM, 2008, PEDIATRICS, V121, pE150, DOI 10.1542/peds.2007-0564

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/36